Cellbiotech to Launch Clinical Study of AD Treatment

Published: 2005-01-06 06:57:00

Updated: 2005-01-06 06:57:00

Cellbiotech Co., a domestic biotechnology venture company, announced on January 4th that it has launched a clinical study of its novel atopic dermatitis (AD) treatment using lactobacillus, which is commonly used for therapeutic purposes on intestinal disorders.

The clinical study will be conducted at Kangnam St.Mary's Hospital of the Catholic University of Korea through June, with a focus o...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.